Literature DB >> 26459118

Sialadenitis after radioiodine therapy. Analysis of factors that influence the response to medical treatment.

Alejandra E Geres1, Paula Szafryk Mereshian2, Silvia Fernández2, Daniel Gonzalo Rey Caro3, Ricardo Castro4, Ricardo Podio4, Silvia Ojeda5.   

Abstract

OBJECTIVES: To assess the incidence of 131I-induced sialadenitis (SD) in patients with differentiated thyroid cancer (DTC), to analyze clinical and other factors related to metabolic radiotherapy that may predict the lack of response to conventional medical therapy (CMT), and to determine the effectiveness of intraductal steroid instillation in patients failing CMT.
MATERIAL AND METHODS: Fifty-two patients with DTC, 45 females (86.5%) and 7 males (13.5%) with a mean age of 44.21±13.3 years (r=17-74) who received ablation therapy with 131I after total thyroidectomy. Patients with diseases and/or medication causing xerostomia were excluded. Patients underwent salivary gland scintigraphy with 99Tc (10mCi).
RESULTS: Eighteen patients (34.62%) had SD and received antibiotics, antispasmodics, and oral steroids for 15 days. They were divided into two groups: responders to medical therapy (n=12, age 44.3±14.4 years, 2 men [17%], 10 women [83%], cumulative dose 225±167.1 mCi) and non-responders to medical treatment, who underwent steroid instillation into the Stensen's duct (n=6 [33%], 2 men [33%], 4 women [67%], age 50±13.8 years, cumulative dose 138.3±61.7 mCi). Scintigraphy showed damage to the parotid and submaxillary glands.
CONCLUSION: Incidence of 131I-induced sialadenitis was similar to that reported by other authors. Age, mean cumulative dose of 131I, and involvement of parotid and submaxillary glands did not condition response to CMT; however, male sex was a conditioning factor. Symptom persistence for more than 15 days makes instillation into the Stensen's duct advisable. This is an effective and safe method to avoid surgical excision of salivary glands.
Copyright © 2015 SEEN. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Cáncer diferenciado de tiroides; Differentiated thyroid cancer; Instilación intraductal; Intraductal instillation; Radioiodine induced sialadenitis; Sialadenitis; Sialoadenitis; Sialoadenitis inducida por radioyodo

Mesh:

Substances:

Year:  2015        PMID: 26459118     DOI: 10.1016/j.endonu.2015.07.006

Source DB:  PubMed          Journal:  Endocrinol Nutr        ISSN: 1575-0922


  3 in total

1.  [Inflammation grading and sialoendoscopic treatment of 131I radioiodine-induced sialadenitis].

Authors:  X Li; J Z Su; Y Y Zhang; L Q Zhang; Y Q Zhang; D G Liu; G Y Yu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-06-18

2.  Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.

Authors:  Arunrat Auttara-Atthakorn; Jaruwan Sungmala; Thunyarat Anothaisintawee; Sirimon Reutrakul; Chutintorn Sriphrapradang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

Review 3.  Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand?

Authors:  Marios Adramerinas; Dimitrios Andreadis; Konstantinos Vahtsevanos; Athanasios Poulopoulos; Kalliopi Pazaitou-Panayiotou
Journal:  Hormones (Athens)       Date:  2021-06-18       Impact factor: 2.885

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.